drugset
drugset / Trial / NCT05579730

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

NCT05579730 ↗

Phase 3 Completed 188 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:

Timeline

Start
2022-10-12
Primary completion
2023-07-22
Completion
2023-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.025 % —
Subject Ketotifen Small molecule 0.035 % —

Indications

conjunctivitis